These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 32461037

  • 1. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM, Study Group for the Uncommon EGFR Mutations in Spain.
    Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
    [Abstract] [Full Text] [Related]

  • 2. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH, Choi CM, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH, Jang TW.
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [Abstract] [Full Text] [Related]

  • 3. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL, Gan JD, Tan JR, Huang YH, Liao J, Liang WT, Deng PB, Fang WF.
    Cancer; 2022 Nov 01; 128(21):3804-3814. PubMed ID: 36069292
    [Abstract] [Full Text] [Related]

  • 5. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.
    Harvey RD, Adams VR, Beardslee T, Medina P.
    J Oncol Pharm Pract; 2020 Sep 01; 26(6):1461-1474. PubMed ID: 32567494
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT.
    Asian Pac J Cancer Prev; 2021 May 01; 22(5):1581-1590. PubMed ID: 34048189
    [Abstract] [Full Text] [Related]

  • 7. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC.
    Target Oncol; 2023 Mar 01; 18(2):195-207. PubMed ID: 36805452
    [Abstract] [Full Text] [Related]

  • 8. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
    Ullas B, Shrinidhi N, Mansi S, Narayan S, Parveen J, Surender D, Joslia JT, Anurag M.
    J Cancer Res Clin Oncol; 2023 Apr 01; 149(4):1541-1549. PubMed ID: 35581383
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S.
    Oncologist; 2022 Apr 05; 27(4):255-265. PubMed ID: 35274704
    [Abstract] [Full Text] [Related]

  • 10. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K, Yu X, Wang H, Huang Z, Xu Y, Gong L, Fan Y.
    Cancer Chemother Pharmacol; 2017 Dec 05; 80(6):1179-1187. PubMed ID: 29063948
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Masood A, Kancha RK, Subramanian J.
    Semin Oncol; 2019 Jun 05; 46(3):271-283. PubMed ID: 31558282
    [Abstract] [Full Text] [Related]

  • 12. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB.
    Oncologist; 2021 Apr 05; 26(4):281-287. PubMed ID: 32969527
    [Abstract] [Full Text] [Related]

  • 13. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C, Ding X, Li M, Luo N, Qi Y, Wang C.
    J Cancer Res Clin Oncol; 2022 May 05; 148(5):1265-1268. PubMed ID: 35230510
    [Abstract] [Full Text] [Related]

  • 14. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B.
    Lung Cancer; 2016 Jun 05; 96():87-92. PubMed ID: 27133756
    [Abstract] [Full Text] [Related]

  • 15. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    Pham CP, Nguyen TTH, Do AT, Nguyen TK, Hoang TAT, Le TA, Vuong DTH, Nguyen DNT, Dang VK, Nguyen TO, Pham VL, Nguyen MH, Vo THT, Do HK, Vu HT, Nguyen TTH, Pham VT, Trinh LH, Nguyen KD, Nguyen HG, Truong CM, Pham TMC, Nguyen TBP.
    BMC Cancer; 2024 Feb 05; 24(1):176. PubMed ID: 38317094
    [Abstract] [Full Text] [Related]

  • 16. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.
    Agraso S, Lázaro M, Firvida XL, Santomé L, Fernández N, Azpitarte C, Leon L, Garcia C, Hudobro G, Areses MC, Campos B, Quiroga N, García J, Casal J.
    Cancer Treat Res Commun; 2022 Feb 05; 33():100646. PubMed ID: 36335799
    [Abstract] [Full Text] [Related]

  • 17. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES.
    J Thorac Oncol; 2020 May 05; 15(5):803-815. PubMed ID: 31931137
    [Abstract] [Full Text] [Related]

  • 18. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH.
    BMC Cancer; 2021 Jan 11; 21(1):52. PubMed ID: 33430803
    [Abstract] [Full Text] [Related]

  • 19. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N, Takahashi F, Tomomatsu K, Obayashi S, Takeuchi T, Takihara T, Hayama N, Oguma T, Aoki T, Asano K.
    Tokai J Exp Clin Med; 2020 Sep 20; 45(3):113-116. PubMed ID: 32901897
    [Abstract] [Full Text] [Related]

  • 20. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
    Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E.
    J Geriatr Oncol; 2023 Jan 20; 14(1):101394. PubMed ID: 36323612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.